| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac2c17e532220d91aca9a28ef60f178b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate |
2012-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82e8e104663f62af3ca8f1160ee06729
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d927283ea7f3afbc84f3c0acffe7f98d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0b9e3d96cba8919f4f48c5f4191912f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0670c99f2a0e7739f78c01c732a9ca99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_585fa063ab2a81359002506d89508edd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_649d5f57d43f04080b72d377bd82eec6 |
| publicationDate |
2013-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013079265-A |
| titleOfInvention |
Buprenorphine wafer for drug replacement therapy |
| abstract |
Disclosed is an oral pharmaceutical dosage form of buprenorphine, an opioid active agent for treating pain that is difficult to divert and / or abuse with drug replacement therapy. An oral pharmaceutical dosage form comprising the opioid active agent buprenorphine or a pharmaceutically acceptable salt thereof, wherein buprenorphine or the pharmaceutically acceptable salt thereof is added orally, preferably immediately after sublingual application. Oral pharmaceutical dosage form to be released. The dosage form is preferably one that releases substantially all of buprenorphine or the pharmaceutically acceptable salt thereof in an oral, preferably less than 2 minutes after sublingual application. The dosage form preferably has a mucoadhesive film-like or wafer-like shape. [Selection figure] None |
| priorityDate |
2006-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |